TrialDiabetes, obesity & metabolism2020

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.

Juan Pablo Frias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.